Lopinavir/ritonavir vs. indinavir/ritonavir in antiretroviral naive HIV-infected patients: Immunovirological outcome and side effects

Antiviral Research

Volumn 62, Issue 1, 2004, Pages 53-56

  Bongiovanni, Marco ^a   Bini, Teresa ^a   Chiesa, Elisabetta ^a   Cicconi, Paola ^a   Adorni, Fulvio ^b   D'Arminio Monforte, Antonella ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b CNR   (Italy)

Author keywords

HAART; IDV RTV; LPV RTV

Indexed keywords

ANTIVIRUS AGENT; CHOLESTEROL; CREATININE; INDINAVIR; LAMIVUDINE; LIVER ENZYME; LOPINAVIR; NELFINAVIR; RITONAVIR; TRIACYLGLYCEROL; ZIDOVUDINE;

ADULT; ALOPECIA; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEATH; DIARRHEA; DRUG EFFICACY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY COLIC; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEPHROTOXICITY; ONYCHOMYCOSIS; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; VIREMIA; VOMITING;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHOLESTEROL; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; MALE; PYRIMIDINONES; RETROSPECTIVE STUDIES; RITONAVIR; RNA, VIRAL; VIREMIA;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 1542613860     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2003.12.002     Document Type: Article

References (10)

1. Arnaiz J.A., Mallolas J., Podzamczer D., Gerstoft J., Lundgren J.D., Cahn P.et al. Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load. AIDS. 17:2003;831-840.
2. Barreiro P., Soriano V., Oller V., Gonzalez-Lahoz J. Potent activity but limited tolerance of ritonavir plus indinavir in salvage interventions. J. Acquir. Immune Defic. Syndr. 24:2000;488.
3. Flexner C. Dual protease inhibitor therapy in HIV-infected patients. Annu. Rev. Pharmacol. Toxicol. 40:2000;649-674.
4. Hsu A., Grannemann G.R., Cao G., Carothers L., Japour A., El-Shourbagy T.et al. Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Antimicrob. Agents Chemother. 42:1998;2784-2791.
5. Rockstroh J.K., Bergmann F., Wiesel W., Rieke A., Thiesen A., Fatkeneuer G.et al. Efficacy and safety of twice daily first-line ritonavir/indinavir plus double nucleoside combination therapy in HIV-infected individuals. German Ritonavir/Indinavir Study Group. AIDS. 14:2000;1181-1185.
6. Sham H.L., Kempf D.J., Molla A., Marsh K.C., Kumar G.N., Chen C.M.et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob. Agents Chemother. 42:1998;3218-3224.
7. Van Heeswijk R.P., Veldkamp A.I., Hoetelmans R.M., Mulder J.W., Schreij G., Hsu A.et al. The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1 infected individuals. AIDS. 13:1999;F95-F99.
8. Walmsley S., Bernstein B., King M., Arribas J., Beall G., Ruane P.et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N. Engl. J. Med. 346(26):2002;2039-2046.
9. Yeni P.G., Hammer S.M., Carpenter C.C., Cooper D.A., Fischl M.A., Gatell J.M.et al. Antiretroviral treatment for adult HIV infection in 2002. Updated recommendations of the International AIDS Society-USA Panel. JAMA. 288:2002;222-232.
10. Young B., Fischl M.A., Wilson H.M., Finn T.S., Jensen E.H., DiNubile M.J.et al. Open label study of a twice-daily indinavir 800-mg/ritonavir 100-mg regimen in protease inhibitor-naïve HIV-infected adults. J. Acquir. Immune Defic. Syndr. 31(5):2002;478-482.